Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q3

9273.TEDINET S100QQJA
Period2022-07-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥16.2bn2022-07-01 → 2023-03-31Cons.Net sales
Revenue¥20.4bn2021-07-01 → 2022-06-30Cons.Net sales (5-year summary)
Revenue¥15.0bn2021-07-01 → 2022-03-31Cons.Net sales
Operating income¥3.3bn2022-07-01 → 2023-03-31Cons.Operating income
Operating income¥3.0bn2021-07-01 → 2022-03-31Cons.Operating income
Ordinary income¥3.2bn2022-07-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥3.8bn2021-07-01 → 2022-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.1bn2021-07-01 → 2022-03-31Cons.Ordinary income
Profit before tax¥3.2bn2022-07-01 → 2023-03-31Cons.Income before income taxes
Profit before tax¥3.1bn2021-07-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.4bn2021-07-01 → 2022-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.0bn2021-07-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss
Net income¥2.0bn2021-07-01 → 2022-03-31Cons.Profit loss
Total assets¥27.5bnat 2023-03-31Cons.Assets
Total assets¥26.2bnat 2022-06-30Cons.Assets
Total assets¥25.4bnat 2022-03-31Cons.Total assets (5-year summary)
Total liabilities¥7.2bnat 2023-03-31Cons.Liabilities
Total liabilities¥7.6bnat 2022-06-30Cons.Liabilities
Net assets / equity¥20.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥18.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥18.3bnat 2022-03-31Cons.Net assets (5-year summary)
Cash and deposits¥9.8bnat 2023-03-31Cons.Cash and deposits
Cash and deposits¥9.1bnat 2022-06-30Cons.Cash and deposits
EPS (basic)¥52.482022-07-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.292023-01-01 → 2023-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.552021-07-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.072021-07-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.82022-01-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio73.7%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio72.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2023-03-31¥16m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥10.2bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥2.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥1.2bn
—segment totalrevenue2022-07-01 → 2023-03-31¥17.5bn
—segment totalrevenue external2022-07-01 → 2023-03-31¥16.2bn
—segment totalrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
—segment totalsegment profit2022-07-01 → 2023-03-31¥3.3bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2022-03-31−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2022-03-31−¥1.4bn
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2022-03-31¥38m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2021-07-01 → 2022-03-31¥10.8bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2021-07-01 → 2022-03-31¥9.4bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2021-07-01 → 2022-03-31¥1.4bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2021-07-01 → 2022-03-31¥1.8bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2021-07-01 → 2022-03-31¥5.6bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2021-07-01 → 2022-03-31¥5.6bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2021-07-01 → 2022-03-31¥1.2bn
—segment totalrevenue2021-07-01 → 2022-03-31¥16.5bn
—segment totalrevenue external2021-07-01 → 2022-03-31¥15.0bn
—segment totalrevenue intersegment2021-07-01 → 2022-03-31¥1.4bn
—segment totalsegment profit2021-07-01 → 2022-03-31¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 361
ItemContextValueUnit
Treasury stockPrior1YearInstant-407000JPY
Treasury stockCurrentQuarterInstant-407000JPY
Shareholders equityPrior1YearInstant18648371000JPY
Shareholders equityCurrentQuarterInstant20291726000JPY
Valuation difference on available for sale securitiesPrior1YearInstant15990000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant12039000JPY
Deferred gains or losses on hedgesPrior1YearInstant1469000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-11403000JPY
Valuation and translation adjustmentsPrior1YearInstant17460000JPY
Valuation and translation adjustmentsCurrentQuarterInstant635000JPY
Net assetsPrior1YearInstant18665832000JPY
Net assetsCurrentQuarterInstant20292362000JPY
Liabilities and net assetsPrior1YearInstant26249934000JPY
Liabilities and net assetsCurrentQuarterInstant27539394000JPY
Net salesPrior1YTDDuration15036396000JPY
Net salesCurrentYTDDuration16159005000JPY
Cost of salesPrior1YTDDuration10506604000JPY
Cost of salesCurrentYTDDuration11358602000JPY
Gross profitPrior1YTDDuration4529792000JPY
Gross profitCurrentYTDDuration4800402000JPY
Selling general and administrative expensesPrior1YTDDuration1480227000JPY
Selling general and administrative expensesCurrentYTDDuration1524274000JPY
Operating incomePrior1YTDDuration3049564000JPY
Operating incomeCurrentYTDDuration3276128000JPY
Interest and dividends income noiPrior1YTDDuration2386000JPY
Interest and dividends income noiCurrentYTDDuration1844000JPY
Foreign exchange gains noiPrior1YTDDuration48032000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Commission fee noiPrior1YTDDuration11617000JPY
Commission fee noiCurrentYTDDuration12436000JPY
Subsidy income noiPrior1YTDDuration2566000JPY
Subsidy income noiCurrentYTDDuration－JPY
Compensation income noiPrior1YTDDuration460000JPY
Compensation income noiCurrentYTDDuration7162000JPY
Gain on transfer of sales rights noiPrior1YTDDuration15181000JPY
Gain on transfer of sales rights noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration3396000JPY
Other noiCurrentYTDDuration4866000JPY
Non operating incomePrior1YTDDuration83642000JPY
Non operating incomeCurrentYTDDuration26310000JPY
Interest expenses noePrior1YTDDuration8960000JPY
Interest expenses noeCurrentYTDDuration5751000JPY
Loss on valuation of investment securities noePrior1YTDDuration－JPY
Loss on valuation of investment securities noeCurrentYTDDuration3071000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration55990000JPY
Settlement package noePrior1YTDDuration16000000JPY
Settlement package noeCurrentYTDDuration－JPY
Voluntary recall related expenses noePrior1YTDDuration36266000JPY
Voluntary recall related expenses noeCurrentYTDDuration13127000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-06-30pass
balance sheet identityconsolidated 2023-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2023-03-31pass
statement vs summary · revenueconsolidated 2021-07-01/2022-03-31pass
statement vs summary · revenueconsolidated 2022-07-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass